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Background: The immune system plays a critical role in the development of co-infections, promoting or preventing
establishment of multiple infections and shaping the outcome of pathogen-host interactions. Its ability to mediate
the interplay between visceral leishmaniasis (VL) and malaria has been suggested, but poorly documented. The present
study investigated whether concomitant infection with Leishmania donovani complex and Plasmodium falciparum
in naturally co-infected patients altered the immunological response elicited by the two pathogens individually.
Results: Circulating levels of interferon (IFN)-γ, interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12p70, IL-13, IL-17A and tumor
necrosis factor (TNF) were assessed in sera of patients infected with active VL and/or malaria and healthy individuals from
Gedarif State, Sudan. Comparative analysis of cytokine profiles from co- and mono-infected patients highlighted significant
differences in the immune response mounted upon co-infection, confirming the ability of L. donovani and P. falciparum
to mutually interact at the immunological level. Progressive polarization towards type-1 and pro-inflammatory cytokine
patterns characterized the co-infected patients, whose response partly reflected the effect elicited by VL (IFN-γ, TNF)
and malaria (IL-2, IL-13), and partly resulted from a synergistic interaction of the two diseases upon each other
(IL-17A). Significantly reduced levels of P. falciparum parasitaemia (P <0.01) were detected in the co-infected
group as opposed to the malaria-only patients, suggesting either a protective or a non-detrimental effect of the
co-infection against P. falciparum infection.
Conclusions: These findings suggest that a new immunological scenario may occur when L. donovani and P.
falciparum co-infect the same patient, with potential implications on the course and resolution of these diseases.
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Co-infection of a host by multiple parasite species is a com-
monly observed condition, where individual susceptibility
and infectiousness are affected at various levels [1-3]. Inter-
microbial competition along with micro-environmental and
immunological conditioning govern the magnitude and
type of interactions across poly-parasitism, promoting or
hampering establishment of multiple parasite infections
and their ability to persist and spread to new patients [4].
At the immunological level, cross-regulation of pathogen-
associated pathways is achieved through cytokine signal-
ing; an integrated network responsible for the controlled
polarization and amplification of immune responses [5,6].* Correspondence: E.v.d.Bogaart@kit.nl
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article, unless otherwise stated.As a result, cytokines secreted in response to one parasite
species may act synergistically or antagonistically with
those elicited by another species, enhancing (cross-im-
munity) or impairing (immune-suppression) simultaneous
control of infections. Cytokine ability to shape the immune
system into efficacious responses arises from their down-
stream actions on the effector mechanisms, with great
variation across different host-parasite systems [6,7]. Con-
versely, upstream cytokine functions are more stereotyp-
ical, while remaining predictive of effector efficacy. Hence,
their characterization in poly-parasitized models provide a
valuable and convenient framework for understanding co-
infection dynamics [6,8].
Visceral leishmaniasis (VL) and malaria are two major
parasitic diseases which overlap geographically and may
co-exist in the same patients [9,10]. Partially sharing the
same host tissue niches, the two infections have thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with clinical outcomes largely dependent on the immuno-
logical status of the host. Obligate intracellular parasites of
the visceralizing Leishmania donovani complex successfully
colonize macrophages and other reticulo-endothelial cells
of the lymphoid system, by altering signaling pathways
associated with parasite killing and adaptive immunity
engagement [11,12]. As a result, phagocytes harboring
Leishmania parasites are incapacitated to function as cyto-
lytic and T-cell priming effectors, causing immune dysfunc-
tion and tissue injury. Resistance to infection is conferred
by development of effective T helper cell 1-type (Th1) re-
sponses, mounted upon release of a pleiotropic interleukin
(IL)-12 and interferon (IFN)-γ cytokine network, and
boosted by pro-inflammatory (tumor necrosis factor
(TNF), IL-23, IL-17A) and Th2-promoting (IL-4) me-
diators [13-17]. Thus, in contrast to the classical Th1-Th2
paradigm suiting predictions of resistance/susceptibility to
cutaneous leishmaniasis [12], clearance of L. donovani ap-
pears to be blunted by induction of the regulatory T cell
subset Tr1, rather than Th2 or Th3 clusters, through an IL-
10 mediated mechanism [18-20]. Anergic IL-10 producing
T cells have also been detected in response to Plasmodium
falciparum infections [21-25], which account for the largest
proportion of malaria disease. Complex, stage-specific
networks of antibody-dependent and cell-mediated inter-
actions provide immunity against Plasmodium spp., with
clinical implications depending on the type and timing of
cytokine release. Early type-1 responses, dominated by
IFN-γ, IL-2 and TNF, have been reportedly associated with
inhibition of liver stage development [26-31], resolution of
acute malaria parasitaemias [32-34] and delay of re-
infection [35], as confirmed by the absolute requirement
of IFN-γ in the effector mechanism of sporozoite-induced
protective immunity [35-38]. Release of these cytokines,
initiated by the innate immune system (Natural killer
(NK) cells, γδT- and αβT-cells) [39-41] and sustained by
Plasmodium-specific CD8+ and CD4+ cells [32,37,39], re-
quires to be timely counterbalanced by a switch to type-2
responses which propagate humoral immunity against
the erythrocytic stage, and limit the pathogenicity of
pro-inflammatory cytokines [42,43]. Similar symptom-
suppressing activities appear to be mediated by IL-10
and transforming growth factor (TGF)-β, which in the
attempt to reduce immunopathology, can interfere
with the protective effects of IFN-γ and TNF and allow
the parasite to grow uncontrollably [21,44,45].
Despite VL and malaria co-infection cases being en-
countered across co-endemic areas, little work has been
done so far to examine the dynamics of this co-infection
and its effect on host immunity. Studies performed in
co-infection murine models of P. chabaudi chabaudi
and L. infantum [46], and of P. yoelii and L. mexicana
amazonensis [47,48] have highlighted an exacerbatingeffect of the two diseases upon each other, particularly
for leishmaniasis, whose enhanced parasite load was at-
tributed to the Plasmodium-triggered release of splenic
IL-4, as assessed by gene expression [46]. Conversely in
golden hamsters, pre-inoculation with different L. infantum
strains resulted in a reduced proliferation of P. berghei, with
no aggravation of the Leishmania infection [49]. Whilst
these discrepancies reflect the difficulty in extrapolating
animal model data, particularly when dealing with multiple
infections, they agree on recognizing the immune system as
a major determinant of Leishmania and Plasmodium spp.
interactions upon co-infection.
In the present study, the cytokine profiles of naturally
co-infected patients were examined. Blood samples from
patients actively infected with VL and/or malaria and
from healthy individuals were collected during an ex-
ploratory survey conducted in Gedarif State, Sudan, and
the level of nine different cytokines selected from across
the four major response arms of the immune system
were assessed simultaneously. The comparative analysis
between co- and mono-infected groups highlighted sub-
stantial differences in the cytokine profile of these pa-
tients and their levels of P. falciparum parasitaemia,
emphasizing the importance of immune-mediated inter-
actions in poly-parasitism.
Methods
Study site, study cases and ethical considerations
The sample collection was performed in February 2011
in the village of Tabarak Allah, an endemic area of L.
donovani, located in Gedarif State, Sudan. Patients were
recruited at Tabarak Allah Hospital, which hosts a VL
treatment center managed by Médecins sans Frontières
since January 2010. Seasonal and unstable malaria pre-
vails in the area, where co-infection rates of 18% to 45%
were recorded amongst Tabarak Allah VL in-patients
(2005-2010) [10].
All individuals included in the study originated from
Gedarif State and aged six years or above. Eligibility for
the study was precluded to children up to age six, due to
immature status of their immune system [50,51]. Indi-
viduals with previous history of VL were also excluded
to ensure relapse cases were not enrolled in the study.
Included patients reported no history of immune-related
disorders, or of ongoing infectious diseases (other than
VL and malaria). Clinical and laboratory examinations
were performed, including assessment of hemoglobin
levels (by HemoCue) and white blood cell (WBC) counts
(by microscopy), and their outcomes recorded on anon-
ymized case record forms. Plasma and serum were ob-
tained from peripheral blood and stored at -70°C until
tested. None of the subjects received anti-leishmanial
chemotherapy before collection of blood samples, while
a minimum of two-week lapse from previous treatment
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consent was obtained from each study participant above
18 years of age or guardian who consented on their be-
half, after providing information on the study aim and
procedures in the local language. The survey was con-
ducted with the approval of the Sudanese Minister of
Health (National Research Ethics Review Committee),
who granted National Ethical Clearance (Nr. 140-10-11).
Diagnostic algorithm
For categorization of study subjects, the following
diagnostic algorithm was implemented. All patients
presenting at the study hospital with symptoms of VL
and/or malaria, including fever, weight loss, hepato-
splenomegaly and anemia, were given physical examin-
ation. Finger-prick blood was assessed by microscopy
for diagnosis of malaria and by direct agglutination test
(DAT) for diagnosis of VL. Assessment of P. falcip-
arum parasitaemia was performed by microscopy,
counting the total number of parasites per 200 WBCs,
as previously described [52]. Artemisinin-based com-
bination therapies were administered to patients posi-
tively diagnosed for malaria. The DAT was performed
on filter paper-spotted blood, using freeze-dried anti-
gen and control sera from the Royal Tropical Institute
(Amsterdam, the Netherlands). A cut-off titer of 3,200
was used, as previously established for the area [53].
Accordingly, patients meeting the WHO clinical defin-
ition for VL (fever for >2 weeks with either anemia or
splenomegaly) [54], and having a DAT titer >3,200, but
no history of VL were diagnosed with primary active
VL and received a 30-day course of parenteral sodium
stibogluconate, conforming to the national policy,
along with the anti-malarial regimen, if required. Pa-
tients who tested negative for both VL and malaria
were excluded from the study and referred to the hos-
pital medical staff for alternative diagnoses. In total,
102 participants (77 VL and/or malaria confirmed pa-
tients and 25 healthy controls) were included at study
entry. Prior to initiation of specific chemotherapies,
peripheral blood was collected from enrolled partici-
pants and processed to obtain serum and plasma sam-
ples. A second subsequent evaluation of all specimens
to confirm (or exclude in case of healthy controls) diag-
nosis of VL and/or malaria was independently per-
formed at the Royal Tropical Institute, the Netherlands.
Specific antibodies to Leishmania were measured in
sera or, when unavailable, filter paper-spotted blood
using the DAT and two commercially available rk39
tests, the DiaMed IT-LeishW (Diamed AG, Cressier sur
Morat, Switzerland) and the Kalazar Detect™ (InBios
International, Inc., Washington, USA). The following
conditions were considered indicative of VL infection:
a) DAT titers ≥3,200, with or without positive rk39 testoutcomes; b) DAT titers =1,600 with at least one con-
firmatory rk39 test; c) DAT titers <1,600 with positive
result in the field (>3,200) and a positive rk39 test.
Samples that did not fulfill these criteria were excluded
from the study (n = 8) or re-categorized (n = 3), if tested
positive for malaria only. Thin and thick blood smears of all
study participants were microscopically re-assessed to con-
firm or exclude presence of P. falciparum parasites. When
slide re-examination resulted in discordant outcomes, a
rapid test (SD Bioline, Standard Diagnostics, Inc., Korea)
for detection of P. falciparum and Plasmodium spp. was
performed on the corresponding serum sample. Positive re-
sults obtained with the serological test were considered
confirmatory of malaria cases (n = 4), while specimens
which tested negative were excluded from the analysis
(n = 2). In addition, five other cases (3 healthy controls,
1 co-infected patient and 1 malaria patient) were excluded
from the study, due to poorly reliable test outcomes, miss-
ing samples or diagnosis of non-P. falciparum malaria.
From the 102 participants included at study entry, 15 were
excluded because they did not match the diagnostic criteria,
narrowing the sample size to 87 cases.
Clinical groups
Group 1
Primary VL cases (n = 29), defined as VL-seropositive
individuals who fulfilled the clinical case definition of
VL and tested negative for malaria.
Group 2
Clinical malaria patients (n = 21). This group included
parasitologically-confirmed cases of P. falciparum malaria
who presented at hospital with clinical symptoms, such
as fever, hepato-splenomegaly and anemia, and lacked
Leishmania-specific antibodies.
Group 3
VL and malaria co-infected patients (n = 15), defined as
VL-seropositive individuals diagnosed with a P. falciparum
malaria infection.
Group 4
Healthy endemic controls (n = 22) with a VL-seronegative
profile and no microscopically detectable malaria in periph-
eral blood.
Cytokine measurement
Cytokine levels in patients’ samples were determined using
a 9-milliplex magnetic bead-based immunoassay (HCYTO-
MAG-60 K, Millipore BV, Amsterdam, the Netherlands),
performed according to manufacturer’s instructions. Briefly,
25 μL of magnetic beads internally labeled with multiple
fluorophores and coated with specific capture antibodies
against one of the nine cytokines (TNF, IL-2, IL-4, IL-6, IL-
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of patient sample and an equal amount of assay buffer.
Standards and quality controls for each cytokine were
mixed likewise. After an overnight incubation followed by
extensive wash to remove unbound proteins, 25 μL of bio-
tinylated detection antibodies was added and the fluores-
cence of the streptavidin-phycoerythrin complex measured
by a MAGPIX® (Luminex, Austin, USA). A minimum of 50
beads per cytokine was measured. Interpolation of sample
concentrations using a five-parameter logistic standard
curve was performed with the MILLIPLEX® Analyst 5.1
software (Merck Millipore, Billerica, USA). The lower de-
tection limits of the assay were: 0.53 pg/mL for TNF,
0.54 pg/mL for IL-2, 0.34 pg/mL for IL-4, 0.97 pg/mL for
IL-6, 0.59 pg/mL for IL-10, 0.74 pg/mL for IL-12p70,
0.57 pg/mL for IL-13, 0.22 pg/mL for IL-17A and 0.17 pg/
mL for IFN-γ. Comparative analysis of cytokine profiles in-
cluded both serum (n = 83) and, when unavailable, plasma
samples (n = 5), since exclusion of plasma assessments had
no effect on the outcome of the analysis.
Statistical analysis
Group-wise comparison of cytokine values was performed
using nonparametric statistics. Mann-Whitney U test and
Kruskal-Wallis test were used to examine whether continu-
ous variables from two or multiple groups, respectively,
originated from the same distribution, whilst comparison of
categorical variables was performed using the Chi-square
test. P values <0.05 were considered indicative of statistical
significance. Spearman’s (rs) rank correlations were com-
puted to assess statistical dependence between cytokine
levels and the corresponding patient demographic/clinicalTable 1 Baseline characteristics of patients with VL and/or ma
Characteristics Pat
1 2
Subjects (n) 29 21
Male/Female (n) 20/8a 11/9b
Age (years) 19 (9-29)d 8 (7-26)
Hb level (g/dL) 9.6 (7.1-12.4) 10.3 (9.1-11.2)
WBC count/mm3 5650 (4925-6900)f 6800 (5900-8000)g
DAT titer 25600 (6400-102400) NA
P.f. parasitaemia
(parasites/μL)
NA 825 (355-2325)j
When not otherwise indicated, data shown represent median and (interquartile ran
Hb = hemoglobin; WBC = white blood cell; DAT = direct agglutination test; P.f. = Plas
Groups 1 to 3 are: 1 = visceral leishmaniasis patients, 2 = malaria patients, 3 = viscer
The Kruskall-Wallis test was used to calculate the P values, except for the variable s
P.f. parasitaemia, for which the Mann-Whitney test was used.
†P value refers to differences between groups 1 and 3 only.
‡P value refers to differences between groups 2 and 3 only.
Sex data based on a 28 patients b 20 patients c 63 patients. Age data based on d 2
patients, h 13 patients and i 42 patients. P. falciparum parasitaemia data based on j
artemether i.m. three weeks prior to diagnosis and their data on P. falciparum parascharacteristics and between each cytokine pair. Data
analysis was conducted with STATA software (College
Station, TX, USA).
Results
Study population
The sex, age, hemoglobin level, WBC count and P. fal-
ciparum infection intensity of patients diagnosed with
VL and/or malaria are summarized in Table 1. With the
exception of malaria parasitaemia, which appeared signifi-
cantly reduced amongst co-infected patients (P <0.01), no
major differences in the baseline distribution of these vari-
ables were observed, with patients sharing most of their
demographic and clinical characteristics. Mild anemia with
normal leukocyte counts characterized most of the actively
infected population, who largely consisted of young boys.
Co-infected patients displayed some intermediate features
between the VL and the malaria groups, including lower
male to female ratio, younger age and milder anemia as
compared with the VL patients.
Circulating cytokine profiles in VL and malaria
mono-infected patients
Significantly increased levels of pro-inflammatory cyto-
kines characterized the VL group compared with the
healthy individuals (circulating cytokine levels of all
study participants are reported in Additional file 1).
Tumor necrosis factor, a marker of local and systemic
inflammation, and the type-1-inducing cytokine IFN-γ
were both strongly up-regulated amongst VL patients, as
compared with healthy controls (P <0.0001) (Figure 1A
and B). Circulating IL-12p70 was also enhanced by thelaria recruited at Tabarak Allah Hospital, Sudan
ient group P
value3 Total
15 65
9/6 40/23c 0.5
16 (9-21) 15 (8-24)e 0.2
9.9 (7.5-11.5) 10.0 (8.4-11.4) 0.8
5400 (4250-7150)h 6050 (4950-7400)i 0.2
12800 (6400-102400) 19200 (6400-102400) 0.9†
53 (38-585)k 370 (51-1113)l 0.005‡
ge).
modium falciparum; NA = not applicable.
al leishmaniasis-malaria co-infected patients.
ex for which the Chi-Square test was used, and for the variables DAT titer and
7 patients and e 63 patients. WBC count data based on f 18 patients, g 11
12 patients, k 10 patients and l 22 patients. Two co-infected patients received
itaemia were excluded to reduce possible bias.
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one control, this interleukin reached or exceeded the de-
tection limit (0.74 pg/mL) in nearly half of the VL
patients (Figure 1C). Similarly, the serum level of IL-6
was negligible in all healthy individuals (<0.97 pg/mL),
but raised to a 10-fold higher value in the VL group
(P <0.0001) (Figure 1D). Systemic inflammation amongst
VL patients was confirmed by IL-17A, whose circulating
levels appeared to be significantly induced (P <0.001)
(Figure 1E). Visceral leishmaniasis cases also exhibited an
increase in their anti-inflammatory and regulatory cytokine
patterns, as shown by the higher amounts of IL-4, and par-
ticularly IL-10 (P <0.0001) (Figure 1F and G). No difference
in the circulating level of IL-2 and IL-13, on the other hand,
distinguished VL-affected and healthy individuals, for
whom the level of these two cytokines resulted mostly
under the assay detection limits (0.54 pg/mL and 0.57 pg/
mL, respectively) (Figure 1H and I).
Clinical malaria cases exhibited an immunological profile
qualitatively similar to that of the VL patients, withFigure 1 (A-I) Cytokines from healthy individuals (Controls) and patie
Additional file 1 for detailed data) are shown as median and interquartile ra
(b) above the box-plot indicate statistically significant differences (P <0.05)
patients, respectively.increased concentrations of TNF, IL-6 and IL-10 (P
<0.0001) and, to a less extent, IFN-γ and IL-17A (P <0.01),
IL-4 and IL-12p70 (P <0.05) (Figure 1A-G). Interleukin-2
and IL-13 persisted at negligible levels (Figure 1H and I).
Circulating cytokine profiles in VL and malaria co-infected
patients
Co-occurrence of malaria and VL in the same patients
deeply altered their immunological response as com-
pared with the single infections. Overall, co-infection of
Leishmania and Plasmodium resulted in a marked eleva-
tion of type-1 and pro-inflammatory cytokine patterns, pre-
sumably triggered by the Leishmania disease. Whereas
comparable amounts of IFN-γ and TNF were detected in
the sera of VL mono- and co-infected patients, the level of
these two cytokines significantly raised when malaria patients
were co-diagnosed with VL (P <0.001 and P <0.01, respec-
tively) (Figure 1A and B). Up-regulation of pro-inflammatory
IL-17A distinguished the co-infected patients from both VL
and malaria mono-infection cases (P <0.05) (Figure 1E),nts with VL and/or malaria. Cytokine levels in each group (see
nge (box), with 10th and 90th percentiles (whiskers). Letters (a) and
as compared with the healthy controls and the co-infected
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upon each other concurred to its release. Strikingly differ-
ent IL-17A concentrations were measured amongst the
co-infected patients, whose demographic and clinical
characteristics, however, did not display any correlation
with the cytokine level. In the co-infected cohort, IL-2 and
IL-13 concentrations exceeded the detection limit with a
higher frequency (4 out of 15 samples) than amongst VL
patients (1 out of 29 samples), resulting in significant differ-
ences (P <0.05) between the two groups (Figure 1H and I).
To exclude that the cytokine profiles observed for VL
and/or malaria infected patients may have been biased
by differences in their demographic and clinical features,
the study population was stratified by sex, age or P. fal-
ciparum parasitaemia (Table 2). For age, patients were
matched by means of two groups (6-15 years, >15 years)
selected to yield similar group-wise compositions, while
for P. falciparum parasitaemia, an infection intensity
>100 parasites/μL of blood was chosen (corresponding
to >0.002%, the level above which patients may become
symptomatic). None of the three variables displayed a
systematic confounding effect on the cytokines exam-
ined here, whose variations amongst the three study
groups remained overall stable (Figure 2). Increased
concentrations of IFN-γ distinguished the co-infected
from the malaria mono-infected patients in all of the
matched groups, whereas significant differences in TNF
levels were observed for men only and for patients above
15 years of age. Importantly, for TNF and IFN-γ the
lower P. falciparum infection intensity recorded amongst
the co-infected cohort did not flaw the comparison with
the malaria patients, as statistically significant differences
still distinguished the two groups after parasitaemia
stratification. Increase in co-infected patient IL-17A level
appeared to be mainly triggered by malaria, as the differ-
ence with this group reduced after age and parasitaemia
matching, but persisted towards VL patients in women only
and in subjects older than 15 years. No significant differ-
ences were observed for the remaining six cytokines,Table 2 Characteristics of patients with VL and/or malaria ma
Characteristics
1
Subjects (n) 29
Male/Female (n) 20/8
Age 6-15 years (n) 13
Median (Interquartile range) 9 (7-13)
Age >15 years (n) 14
Median (Interquartile Range) 26 (20-35)
P.f. parasitaemia >100 parasites/μL (n) NA
Median (Interquartile range) NA
P.f. = Plasmodium falciparum; NA = not applicable.
Groups 1 to 3 are: 1 = visceral leishmaniasis patients, 2 = malaria patients, 3 = visceincluding IL-2 and IL-13, for which most patients displayed
negligible levels (data not shown).
Correlation between circulating cytokines in VL and
malaria co-infected patients
Specific mechanisms cross-regulate the production of
cytokines, with positive and negative feed-back loops to
control secretion of signaling molecules. To understand the
link interconnecting each of the cytokines examined here,
their correlation was investigated using the Spearman’s
correlation rank test. As shown in Table 3, multiple positive
correlations were identified between pro-inflammatory
(TNF vs. IL-6) and type-1 cytokines (IFN-γ vs. IL-12p70),
as well as for type-1 vs. pro-inflammatory (IFN-γ & IL-
12p70 vs. TNF, IL-6 & IL-17A), and type-2 vs. pro-
inflammatory (IL-13 vs. TNF, IL-6 & IL-17A) and type-1
cytokines (IL-13 vs. IL-12p70 & IFN-γ). Conversely, no cor-
relation could be identified between the examined cytokines
and the DAT titers as well as the P. falciparum parasit-
aemia of co-infected patients (data not shown).
Discussion
The ability of Leishmania and Plasmodium parasites to
manipulate host immunity and co-inhabit part of the
same lymphoid tissues suggests the possibility that the
two diseases may interact with each other, when co-
occurring in the same host. This is demonstrated for the
first time in naturally co-infected patients by the pilot
study presented here. Comparative analysis of cytokine
profiles from co- and mono-infected patients highlighted
substantial variations in the immune response mounted
upon co-infection, confirming the ability of L. donovani
and P. falciparum to mutually interact at the immuno-
logical level. Patients harboring both leishmanial and mal-
arial parasites responded with an overall increase in type-1
and pro-inflammatory cytokine release, which partly
reflected the effect elicited by VL (TNF, IFN-γ) and
malaria (IL-2), and partly resulted from a synergistic inter-
action of the two diseases upon each other (IL-17A).tched by sex, age or P. falciparum parasitaemia
Patient group
2 3 Total
21 15 65
11/9 9/6 40/23
14 7 34
8 (7-9) 9 (7-10)
7 8 29
27 (25-30) 19 (17-27)
12 4 16
825 (355-2325) 640 (290-1088)
ral leishmaniasis-malaria co-infected patients.
Figure 2 Cytokines from patients with VL and/or malaria matched by sex, age and P. falciparum parasitaemia. Cytokine levels in each
group are shown as median and interquartile range. P <0.05*; P <0.01**. 6-15y = age 6-15 years; >15y = age >15 years; P.f. >100 = P. falciparum
parasitaemia >100 parasites/μL.
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exceeded the amounts found in VL patients and displayed
positive correlations with most of the examined cytokines.
Although this trend can be seen as an attempt of the im-
mune system to contain the effects elicited by type-1 and
pro-inflammatory cytokines (these patients exhibited some
of the highest concentrations of IFN-γ, TNF and IL-17A),
the finding remains poorly representative, reflecting the
response of 4 patients only, with the remaining co-
infected patients (n = 11) displaying negligible levels of
IL-13 just as most of VL and malaria patients.
Measurement of IL-17A levels allowed to distinguish
the co-infected patients from both VL and malaria
mono-infected counterparts, indicating that both dis-
eases synergistically concurred to its up-regulation. Bet-
ter known for its pro-inflammatory effects in allergic
and autoimmune conditions, IL-17 has been recently
implicated in the protective immunity towards bacterial,
fungal and protozoan infections [55], where it is thought
to mediate recruitment of neutrophils to the epithelial
and mucosal surfaces and induce production of anti-
microbial peptides [55,56]. Its release by CD4+ Th17
cells has been associated with resistance to human VL
[57] and positive resolution of murine L. donovani infec-
tions [58], suggesting that Th17 and Th1 cytokines may
play complementary roles in parasite clearance. Hence,Table 3 Correlation coefficients between cytokine levels from
Tabarak Allah Hospital, Sudan
Cytokine co
Coefficient rs
† TNF IL-6 IL-17A IFN-γ
TNF 0.80*** 0.63* 0.69**
IL-6 0.55* 0.68**
IL-17A 0.64**
IFN-γ
IL-12p70
IL-13
IL-10
IL-4
†Spearman’s (rs) rank correlations were computed and statistical significance was cothe increased concentrations of IL-17A found in the co-
infected vs. the VL mono-infected cohort, besides the
already elevated IFN-γ and IL-12p70, may be indicative
of a favorable, possibly improved, prognosis for VL,
though the present data do not allow to draw conclu-
sions in this respect. In support of this speculation is the
finding of a recent study conducted in Barbar el Fugarra,
a Sudanese village situated only a few tens of kilometers
away from Tabarak Allah Hospital (where patients in this
study were recruited), in which peripheral blood mono-
nuclear cells (PBMCs) isolated from VL-seropositive indi-
viduals who did not develop disease at any time during the
6-year survey, secreted significantly higher IL-17 levels
when challenged with L. donovani in comparison with VL-
seropositive individuals who became symptomatic within
6 months from the evaluation [57]. Interestingly, malaria
appeared as the major trigger of this IL-17A up-regulation
in co-infected patients, given that no relationship between
patients’ demographic and clinical variables and the corre-
sponding IL-17A serum level could be identified in this
group (nor in any other group). Expansion of IL-17-
producing cells (either CD4+ T cells, CD8+ T cells or mac-
rophages) and related cytokines (IL-17, IL-22 and IL-23)
has been observed in P. vivax natural infections [59] as well
as P. berghei, P. chabaudi and P. fragile animal models
[60-62], where these interleukins have been shown toVL-malaria co-infected patients recruited at
rrelation
IL-12p70 IL-13 IL-10 IL-4 IL-2
0.66** 0.75** 0.59* 0.40 0.20
0.82*** 0.68** 0.61* 0.27 0.13
0.68** 0.70** 0.14 0.30 0.20
0.75** 0.78** 0.46 0.59* 0.39
0.85*** 0.34 0.19 0.34
0.28 0.32 0.53*
0.14 0.12
-0.15
nsidered when P <0.001***, P <0.01** or P <0.05*.
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[59-61]. Conversely, a clear role of IL-17 immunity in P. fal-
ciparum infections is yet to be demonstrated. Transcrip-
tional profiling of PBMCs isolated from P. falciparum-
infected patients has recently highlighted a Th17/Thαβ
driven bias in the immune response mounted against mal-
aria, with up-regulation of several Th17- and neutrophil-
related genes [63,64] and induction of a NK cell-mediated
humoral response via interferon α and β [63]. Triggering of
this Thαβ immunity, in particular, was shown to inhibit the
IL-12 driven Th1 response [63], necessary for boosting
clearance of malaria parasites [29,65-67], particularly during
the pre-erythocytic stage, when cell-mediated immunity is
essential for control of infection. If induction of a Th17 re-
sponse may, therefore, indirectly impair host ability to con-
tain malaria through suppression of macrophage activities,
the IFN-γ dominant response elicited by VL may partially
compensate for this deficiency and act as a pre-priming
stimulus upon Plasmodium infection, for the development
of malaria adaptive immunity (via NKT cells, e.g.) and the
nitric oxygen-dependent suppression of intra-hepatocytic
forms. The above-shown data confirm the leading presence
of IFN-γ (P <0.0001), followed by TNF (P <0.05) and IL-4
(P <0.05), in the sera of VL patients as compared with the
malaria ones, and clearly identify a shift towards type-1/
pro-inflammatory polarization when malaria co-occurred
with VL. In addition, a significantly reduced P. falciparum
infection intensity was observed among co-infected pa-
tients, suggesting improved tolerance of these individuals to
the malaria disease. Whether this reduced susceptibility re-
sulted from the VL-driven pre-immune response remains
to be demonstrated. The pioneer work of Adler et al. on
co-infected hamsters [49] highlighted a reduced prolifera-
tion of P. berghei for effect of the Leishmania infection,
supporting the idea of a VL-triggered cross-immunity
against malaria, whereas the more recent mouse model
data [46-48] seem to suggest the opposite conclusion. It is
worthy to note that animals were challenged with blood-
stage parasites rather than with sporozoites, bypassing the
naturally occurring liver phase against which cellular im-
munity is most effective and most likely to be developed in
response to VL (Leishmania parasites visceralize in the
liver, too). Moreover, mice and hamsters are not equally
representative models of the VL disease, whose clinico-
pathological features in humans are better reproduced by
the golden hamster model [68].
The exploratory nature of this survey implies its design
and findings are limited by the small sample sizes and the
lack of subject matching between groups, although no sig-
nificant difference in the distribution of patients’ demo-
graphic and clinical features was observed. Diagnosis of VL
in clinical suspects was confirmed by serology, according to
the national policy, precluding any analysis on parasite
loads and their link with cytokine profiles. Assessment ofmalaria parasitaemia, on the contrary, was performed on
peripheral blood films, but the low sensitivity of microscopy
observation inevitably limits its reliability as a quantitative
assay. Moreover, in the absence of a molecular screening of
the recruited individuals, the risk of sub-microscopy mal-
aria infections being carried by the VL patients and/or ap-
parently healthy controls cannot be excluded. Malaria
mono- and co-infected patients exhibited different P. falcip-
arum blood parasitaemias. Whether these differences are
linked to their particular diagnosis, however, is unknown,
as patients were recruited sequentially and discernment be-
tween clinical and sub-clinical co-infection cases is not pos-
sible if one of the two diseases manifests with symptoms.
Therefore, recruitment of asymptomatic, but parasitaemic
individuals for each of the two infections may be useful to
control for non-homogeneous group-wise comparisons.
Absence of pre-existent disorders was based on patient
reporting only, with no diagnostic procedure performed,
other than those ones aimed to confirm VL or malaria. Fi-
nally, longitudinal rather than cross-sectional assessments
should be endorsed, as they could help identifying those
fundamental associations amongst parasite load, cytokine
response and clinical picture which are keys to the inter-
pretation of present data. Similar studies may not only clar-
ify the exact role of the VL-malaria co-infection on P.
falciparum proliferation, but they would be pivotal for un-
derstanding the clinical implications that arise from the dif-
ferent cytokine profiles.
Conclusions
Immune-mediated interactions between L. donovani
complex and P. falciparum appear to shape the im-
munological response taking place in the co-infected
host and possibly the intensity of infections that follow.
Similar scenarios have been depicted with other malaria
co-infections, indicating that the potential implications
arising from multiple pathogen-host relations should be
addressed when designing malaria vaccine trials. Careful
consideration of parasite interplays should be taken
when defining the best strategy for clinical management
of VL-malaria co-infections, to ensure that immune
homeostasis may be restored without harming patient’s
clinical course.
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